Patent 7592352 was granted and assigned to Smithkline Beecham Limited on September, 2009 by the United States Patent and Trademark Office.
This invention relates to newly identified compounds for treating and preventing tumors and cancers, and methods for treating proliferative diseases associated with the imbalance or inappropriate activity of tyrosine kinases implicated in proliferative diseases.